as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹423.75
Change
+1.75 (0.41%)
Open
₹418.95
Prev. Close
₹422.0
Day High
₹427.0
Day Low
₹416.35
Volume Analysis
Traded
31,206
Delivered
15,859
Delivery %
50.82%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹439.04 | ₹433.02 | ₹428.39 | ₹422.37 | ₹417.74 | ₹411.72 | ₹407.09 |
| Fibonacci | ₹433.02 | ₹428.95 | ₹426.44 | ₹422.37 | ₹418.3 | ₹415.79 | ₹411.72 |
| Camarilla | ₹426.68 | ₹425.7 | ₹424.73 | ₹422.37 | ₹422.77 | ₹421.8 | ₹420.82 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+24.12%
1 Week
-2.73%
1 Month
+4.29%
3 Months
+4.1%
6 Months
+46.78%
1 Year
+18.37%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹97.71
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.52%
Net margin 7.44% × asset turnover 0.7x × equity multiplier 2.02x
Company Overview
Sector
Healthcare
Market Cap
₹4,237 Cr
P/E (TTM)
57.7
ROE
10.1%
Book Value
₹66.3
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Gufic Biosciences Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Financial Strength (82/100), while Valuation (10/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling.
TopFund Score — Fundamentals Quality
52/100 — AverageData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 6.36 times its book value
- −Company has a low return on equity of 12.8% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
NSE rejected waiver; Gufic BioSciences must pay ₹1.72 lakh penalty by October 3, 2026.
CRISIL reaffirmed Gufic BioSciences' A-/Stable and A2+ ratings; bank facilities increased to Rs. 516 crore.
42nd AGM voting results: five resolutions passed, including 10% final dividend and reappointment of Whole Time Director.
Gufic Biosciences held its 42nd AGM on September 4, 2026; approved 10% final dividend and director reappointments.
Ami Shah promoted to Head-Legal; Pinak Padhya promoted to President-Sales & Marketing from September 2, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 224 | 237 | 231 | 252 | 261 |
| Expenses + | 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 | 205 | 214 |
| Operating Profit | 39 | 36 | 34 | 36 | 39 | 34 | 26 | 33 | 38 | 33 | 47 | 47 |
| OPM % | 18.0% | 18.0% | 18.0% | 18.0% | 19.0% | 16.0% | 13.0% | 15.0% | 16.0% | 14.0% | 19.0% | 18.0% |
| Other Income + | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 |
| Interest | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit before tax | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 17 | 23 | 18 | 29 | 30 |
| Tax % | 25.0% | 25.0% | 26.0% | 26.0% | 26.0% | 26.0% | 27.0% | 24.0% | 26.0% | 30.0% | 24.0% | 26.0% |
| Net Profit + | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 13 | 17 | 12 | 22 | 22 |
| EPS in Rs | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales + | 807 | 820 | 944 | 981 |
| Expenses + | 657 | 684 | 793 | 816 |
| Operating Profit | 150 | 136 | 151 | 165 |
| OPM % | 19.0% | 17.0% | 16.0% | 17.0% |
| Other Income + | 0 | 4 | 3 | 2 |
| Interest | 17 | 25 | 37 | 37 |
| Depreciation | 17 | 21 | 31 | 31 |
| Profit before tax | 116 | 94 | 87 | 99 |
| Tax % | 26.0% | 26.0% | 26.0% | — |
| Net Profit + | 86 | 70 | 64 | 73 |
| EPS in Rs | 9 | 7 | 6 | 7 |
| Dividend Payout % | 1.0% | 1.0% | 2.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Reserves | 523 | 591 | 655 |
| Borrowings + | 333 | 336 | 405 |
| Other Liabilities + | 227 | 232 | 273 |
| Total Liabilities | 1,093 | 1,169 | 1,342 |
| Fixed Assets + | 159 | 506 | 491 |
| CWIP | 307 | 22 | 22 |
| Investments | 2 | 2 | 2 |
| Other Assets + | 625 | 640 | 827 |
| Total Assets | 1,093 | 1,169 | 1,342 |
| Equity Capital | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from Operating Activity + | -7 | 123 | 45 |
| Cash from Investing Activity + | -102 | -71 | -31 |
| Cash from Financing Activity + | 82 | -37 | 32 |
| Net Cash Flow | -27 | 15 | 46 |
| CFO/OP | 13 | 107 | 38 |
| Free Cash Flow | -116 | 52 | 14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 22.64% | 25.29% | 25.17% | 24.89% | 24.75% | 24.2% | 23.79% | 23.81% | 23.51% | 23.3% | 23.23% | 23.36% |
| Promoters | 75.0% | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% | 72.51% | 72.5% | 72.5% | 72.5% | 72.5% |
| FII | 0.72% | 0.47% | 0.12% | 0.23% | 0.23% | 0.3% | 0.31% | 0.32% | 0.33% | 0.44% | 0.42% | 0.47% |
| DII | 1.63% | 1.72% | 2.2% | 2.38% | 2.51% | 2.99% | 3.39% | 3.38% | 3.66% | 3.74% | 3.83% | 3.67% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gufic Biosciences Ltd. (this stock) | 4,237 | 57.7 | 6.37 | 10.1% |
| Sms Pharmaceuticals Ltd. | 4,448 | 43.4 | 5.66 | 14.3% |
| Aarti Drugs Ltd. | 3,991 | 20.7 | 2.57 | 13.4% |
| Unichem Laboratories Ltd | 3,870 | 31.7 | 1.42 | 3.17% |
| Zota Health Care Limited | 4,629 | — | 6.69 | -15.0% |
| Kwality Pharmaceuticals L | 3,824 | 46.8 | 11.48 | 22.6% |
| Solara Active Pha Sci Ltd | 3,587 | 840.0 | 2.14 | -0.13% |
Which Mutual Funds Hold Gufic Biosciences Ltd.?
Frequently Asked Questions about Gufic Biosciences Ltd.
Gufic Biosciences Ltd. (GUFICBIO) closed at ₹423.75 on NSE on 25 September 2026, up 1.75 (0.41%) from the previous close.
Gufic Biosciences Ltd. trades on the NSE (National Stock Exchange of India) under the symbol GUFICBIO.
Gufic Biosciences Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 57.7.
Gufic Biosciences Ltd. has a dividend yield of 0.02%.
Gufic Biosciences Ltd.'s 52-week high is ₹468.0 and its 52-week low is ₹268.0.
Gufic Biosciences Ltd. has a market capitalisation of ₹4,237 crore.
Gufic Biosciences Ltd. has a TopFund Quality Score of 52/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gufic Biosciences Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.